Wellington Management Group LLP Has $504,000 Position in Royalty Pharma plc (NASDAQ:RPRX)

Wellington Management Group LLP lessened its stake in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 69.0% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 17,806 shares of the biopharmaceutical company's stock after selling 39,598 shares during the period. Wellington Management Group LLP's holdings in Royalty Pharma were worth $504,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Aurora Investment Counsel boosted its holdings in shares of Royalty Pharma by 1.0% in the third quarter. Aurora Investment Counsel now owns 50,441 shares of the biopharmaceutical company's stock valued at $1,427,000 after acquiring an additional 512 shares in the last quarter. Xponance Inc. lifted its position in Royalty Pharma by 1.9% in the second quarter. Xponance Inc. now owns 31,704 shares of the biopharmaceutical company's stock worth $836,000 after purchasing an additional 606 shares during the period. EverSource Wealth Advisors LLC boosted its stake in Royalty Pharma by 32.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company's stock valued at $76,000 after purchasing an additional 655 shares in the last quarter. Values First Advisors Inc. increased its position in shares of Royalty Pharma by 7.6% during the 3rd quarter. Values First Advisors Inc. now owns 10,412 shares of the biopharmaceutical company's stock valued at $295,000 after purchasing an additional 738 shares during the period. Finally, Phillips Wealth Planners LLC raised its stake in shares of Royalty Pharma by 10.2% in the 3rd quarter. Phillips Wealth Planners LLC now owns 8,733 shares of the biopharmaceutical company's stock worth $246,000 after buying an additional 808 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company's stock.

Wall Street Analyst Weigh In

RPRX has been the subject of several research reports. StockNews.com raised Royalty Pharma from a "hold" rating to a "buy" rating in a research note on Tuesday, November 5th. Citigroup lowered their price objective on shares of Royalty Pharma from $60.00 to $40.00 and set a "buy" rating on the stock in a research note on Friday, October 25th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $41.67.

Royalty Pharma Trading Up 2.6 %

Shares of NASDAQ:RPRX traded up $0.64 during mid-day trading on Friday, hitting $24.92. The stock had a trading volume of 7,574,639 shares, compared to its average volume of 2,691,117. The company's 50 day moving average is $26.43 and its 200-day moving average is $27.15. Royalty Pharma plc has a 12-month low of $24.05 and a 12-month high of $31.66. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.54 and a current ratio of 1.54. The company has a market cap of $14.68 billion, a PE ratio of 12.91, a P/E/G ratio of 4.36 and a beta of 0.46.

Royalty Pharma Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th were issued a dividend of $0.21 per share. The ex-dividend date was Friday, November 15th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.37%. Royalty Pharma's dividend payout ratio is 43.52%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.